Table 1.
Pharmacodynamic properties of CBG at related receptors.
| Receptor | Affinity (nM) | Function | Reference |
|---|---|---|---|
| CB1 | 440–1045 (Ki) | Weak agonist | [15,16] |
| CB2 | 153.4–1225 (Ki) | Partial agonist | [15] |
| TRPA1 | 700 | Agonist | [27,28] |
| TRPV1 | 1300 | Agonist | [29,30] |
| TRPV2 | 1720 | Agonist | [20,28] |
| TRPV3 | 1000 | Agonist | [20,28] |
| TRPV4 | 5100 | Agonist | [20,28] |
| TRPM8 | 160 | Antagonist | [31,32] |
| α2AR | 0.2–72.8 | Agonist | [15] |
| 5-HT1A | 51.9 | Antagonist | [21,22,33] |
| PPARγ | 1270 | Agonist | [16] |
Abbreviations: CB1, cannabinoid receptor type 1; CB2, cannabinoid receptor type 2; TRPV1, transient receptor potential vanilloid type 1; TRPV2, transient receptor potential vanilloid type 2; TRPV3, transient receptor potential vanilloid type 3; TRPV4, transient receptor potential vanilloid type 4; TRPM8, transient receptor potential cation channel 8; α-2 adrenoceptor, alpha-2 (α2) adrenergic receptor; 5-HT1A, serotonin receptor 1A; PPARγ, peroxisome proliferator-activated receptor gamma.